Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 19;8(4):779.
doi: 10.3390/vaccines8040779.

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease

Joan G Tell  1 , Beth-Ann G Coller  1 , Sheri A Dubey  1 , Ursula Jenal  2 , William Lapps  1 , Liman Wang  1 , Jayanthi Wolf  1
Affiliations
Review

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease

Joan G Tell et al. Vaccines (Basel). .

Abstract

rVSVΔG-ZEBOV-GP is a live, attenuated, recombinant vesicular stomatitis virus (rVSV)-based vaccine for the prevention of Ebola virus disease caused by Zaire ebolavirus. As a replication-competent genetically modified organism, rVSVΔG-ZEBOV-GP underwent various environmental evaluations prior to approval, the most in-depth being the environmental risk assessment (ERA) required by the European Medicines Agency. This ERA, as well as the underlying methodology used to arrive at a sound conclusion about the environmental risks of rVSVΔG-ZEBOV-GP, are described in this review. Clinical data from vaccinated adults demonstrated only infrequent, low-level shedding and transient, low-level viremia, indicating a low person-to-person infection risk. Animal data suggest that it is highly unlikely that vaccinated individuals would infect animals with recombinant virus vaccine or that rVSVΔG-ZEBOV-GP would spread within animal populations. Preclinical studies in various hematophagous insect vectors showed that these species were unable to transmit rVSVΔG-ZEBOV-GP. Pathogenicity risk in humans and animals was found to be low, based on clinical and preclinical data. The overall risk for non-vaccinated individuals and the environment is thus negligible and can be minimized further through defined mitigation strategies. This ERA and the experience gained are relevant to developing other rVSV-based vaccines, including candidates under investigation for prevention of COVID-19.

Keywords: ERA; ERVEBO®; GMO; Zaire ebolavirus; environmental impact; rVSV; recombinant vaccine; shedding; vesicular stomatitis virus; viremia.

PubMed Disclaimer

Conflict of interest statement

J.G.T., B-A.G.C., S.A.D., W.L., L.W., and J.W. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, who may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. U.J. served as a consultant to Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, in connection with the work described in this manuscript. Employees of the funder were involved in the design of the original research summarized in this article; in the collection, analyses and interpretation of data; and in the writing of the manuscript. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Figures

Figure 1
Figure 1
Hypothesized viral life cycle for wild-type (a) Ebola virus and (b) vesicular stomatitis virus (VSV). Shown are the enzootic cycles (i.e., the predominant, long-term natural host reservoirs of the virus and transmission vectors) and epizootic cycles (i.e., spillover of the virus into other susceptible species and/or alternative transmission vectors). The main natural host reservoir of Ebola virus is thought to be certain species of Old World fruit bats, but the virus is capable of transmission to many other mammalian species [1,7,8,9,10]. The natural host reservoir of VSV is thought to be mainly small rodents, such as deer mice, with sandflies acting as transmission vectors; however, VSV is also capable of infecting many other animal species and can be transmitted via other insects [15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32]. a Pool feeders, i.e., hematophagous arthropods that lacerate their host’s blood vessels and then consume the pooled blood. b Vessel feeders, i.e., hematophagous arthropods that consume blood by directly inserting their mouthparts into the lumen of their host’s capillary blood vessels.
Figure 1
Figure 1
Hypothesized viral life cycle for wild-type (a) Ebola virus and (b) vesicular stomatitis virus (VSV). Shown are the enzootic cycles (i.e., the predominant, long-term natural host reservoirs of the virus and transmission vectors) and epizootic cycles (i.e., spillover of the virus into other susceptible species and/or alternative transmission vectors). The main natural host reservoir of Ebola virus is thought to be certain species of Old World fruit bats, but the virus is capable of transmission to many other mammalian species [1,7,8,9,10]. The natural host reservoir of VSV is thought to be mainly small rodents, such as deer mice, with sandflies acting as transmission vectors; however, VSV is also capable of infecting many other animal species and can be transmitted via other insects [15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32]. a Pool feeders, i.e., hematophagous arthropods that lacerate their host’s blood vessels and then consume the pooled blood. b Vessel feeders, i.e., hematophagous arthropods that consume blood by directly inserting their mouthparts into the lumen of their host’s capillary blood vessels.
Figure 2
Figure 2
Molecular structure of the chimeric rVSVΔG-ZEBOV-GP live, recombinant vaccine compared with wtVSV. L, large protein. M, matrix protein. N, nucleoprotein. P, phosphoprotein. VSV-G, vesicular stomatitis virus envelope glycoprotein. ZEBOV-GP, Ebola virus envelope glycoprotein.
Figure 3
Figure 3
Steps required to conduct an ERA for a GMO medicinal product under EMA regulations (left-hand column), illustrated by specific assessment examples from the ERA for rVSVΔG-ZEBOV-GP (right-hand column).
Figure 4
Figure 4
rVSVΔG-ZEBOV-GP shedding and excretion rates among participants in the V920-007 phase 1 clinical trial for whom corresponding data were available.
Figure 5
Figure 5
rVSVΔG-ZEBOV-GP viremia rates, over the first 3 days post-inoculation, among participants in the V920-004 phase 1 clinical trial.
See this image and copyright information in PMC

References

    1. Jacob S.T., Crozier I., Fischer W.A., 2nd, Hewlett A., Kraft C.S., Vega M.A., Soka M.J., Wahl V., Griffiths A., Bollinger L., et al. Ebola Virus Disease. Nat. Rev. Dis. Primers. 2020;6:13. doi: 10.1038/s41572-020-0147-3. - DOI - PMC - PubMed
    1. Canady D., Weil N.C., Miller C., Shantha J.G., Bastien G., Yeh S. Ophthalmic and Psychosocial Sequelae in Ebola Virus Disease Survivors: Ongoing Need for Health Systems Strengthening across Disciplines. Expert Rev. Anti. Infect. Ther. 2020:1–3. doi: 10.1080/14787210.2020.1808461. - DOI - PMC - PubMed
    1. Etard J.F., Sow M.S., Leroy S., Toure A., Taverne B., Keita A.K., Msellati P., Magassouba N., Baize S., Raoul H., et al. Multidisciplinary Assessment of Post-Ebola Sequelae in Guinea (Postebogui): An Observational Cohort Study. Lancet Infect. Dis. 2017;17:545–552. doi: 10.1016/S1473-3099(16)30516-3. - DOI - PubMed
    1. Mattia J.G., Vandy M.J., Chang J.C., Platt D.E., Dierberg K., Bausch D.G., Brooks T., Conteh S., Crozier I., Fowler R.A., et al. Early Clinical Sequelae of Ebola Virus Disease in Sierra Leone: A Cross-Sectional Study. Lancet Infect. Dis. 2016;16:331–338. doi: 10.1016/S1473-3099(15)00489-2. - DOI - PMC - PubMed
    1. Wiedemann A., Foucat E., Hocini H., Lefebvre C., Hejblum B.P., Durand M., Kruger M., Keita A.K., Ayouba A., Mely S., et al. Long-Lasting Severe Immune Dysfunction in Ebola Virus Disease Survivors. Nat. Commun. 2020;11:3730. doi: 10.1038/s41467-020-17489-7. - DOI - PMC - PubMed

Grants and funding